Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19

Background: Baricitinib is a Janus kinase (JAK) inhibitor with a broader anti-inflammatory activity than tocilizumab and an antiviral potential although no head-to-head trials are available. The benefits of adding baricitinib to patients with COVID-19 experiencing clinical progression despite the st...

Descripción completa

Detalles Bibliográficos
Autores principales: Masiá, Mar, Padilla, Sergio, García, José Alberto, García-Abellán, Javier, Navarro, Andrés, Guillén, Lucía, Telenti, Guillermo, Mascarell, Paula, Botella, Ángela, Gutiérrez, Félix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606519/
https://www.ncbi.nlm.nih.gov/pubmed/34820393
http://dx.doi.org/10.3389/fmed.2021.749657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606519/
https://www.ncbi.nlm.nih.gov/pubmed/34820393
http://dx.doi.org/10.3389/fmed.2021.749657

Ejemplares similares